Brookline Reaffirms Price Target for Moderna (MRNA) After Strong mRNA-1283 Vaccine Results

Moderna, Inc. (NASDAQ:MRNA) ranks among the best biotech stocks to buy. Following solid trial results for Moderna, Inc. (NASDAQ:MRNA)’s refrigerator-stable COVID-19 vaccine, Brookline Capital Markets reaffirmed its Buy rating and $198 price target for the company on September 23. Photo by Ian Hutchinson on Unsplash According to the new data, mNEXSPIKE/mRNA-1283 increased neutralizing antibodies against the LP.8.1 variant by an average of more than sixteen times, which Brookline regarded as “remarkably s ...